Calidar

Executive Summary

Calidar is a San Diego-based medical technology company pioneering next-generation X-ray diffraction imaging for breast cancer diagnostics. Founded in 2018, the company is developing its patented 4D Mammography technology, which aims to noninvasively reveal molecular-level signatures of disease to enable earlier and more accurate detection. Its platform measures tissue 'fingerprints' via X-ray scatter, providing a new dimension of data beyond traditional anatomical imaging. By capturing molecular information, Calidar's approach has the potential to improve diagnostic accuracy and reduce false positives, addressing key limitations of current mammography. The company is private and early-stage, with no disclosed funding or valuation, but its innovative technology positions it in the growing field of advanced breast cancer diagnostics. Calidar's success will depend on clinical validation, regulatory clearance, and commercialization partnerships.

Upcoming Catalysts (preview)

• Q4 2026First-in-human study initiation70% success
• Q3 2026Series A funding announcement60% success
• Q2 2026Key opinion leader (KOL) engagement or clinical collaboration80% success